Medivir Initiates Collaboration with Swedish University of Agricultural Sciences to Develop New Drugs for Bacterial Infections

Medivir Initiates Collaboration with Swedish University of Agricultural Sciences to Develop New Drugs for Bacterial Infections

HUDDINGE, Sweden, Jun 26, 2012 (BUSINESS WIRE) -- Regulatory News:

Medivir AB (omx:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced today that it has initiated a collaboration with researchers at the Swedish University of Agricultural Sciences aimed at identifying and developing new drugs against bacteria that have become resistant to current antibiotics.

The researchers at the Swedish University of Agricultural Sciences (SLU) have extensive experience of isolating new microorganisms and their metabolites (intermediates and products of metabolism) with which microorganisms compete with each other in nature. These low molecular-weight chemical compounds with potentially novel mechanisms of action may serve as the starting point for developing new antibiotics to treat severe bacterial infections.

Medivir will further develop the substances that the SLU researchers identify in this early screening collaboration. Medivir will pay SLU a compensation for research services during the screening collaboration and a minor part of future revenues associated with any further development or commercialization of future substances.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world-class expertise in polymerase and protease drug targets and drug development, which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a protease inhibitor in phase III clinical development for treatment of hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialization of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese(R)/Xerclear(R), is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia under the brand name ZoviDou.

For more information about Medivir, please visit the website: www.medivir.com

For more information about SLU, please visit the website: www.slu.se

This information was brought to you by Cision http://www.cisionwire.com

SOURCE: Medivir


       
        Medivir
        Medivir Mobile: +46 708 537292
        Rein Piir, EVP Corporate Affairs & IR
        M:Communications [email protected]
        Europe:
        Mary-Jane Elliott,
        Amber Bielecka,
        Hollie Vile +44(0)20 7920 2330

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.